Developer docs
API playgroundTry for free, no card

Search company profiles

Novaliq

Full company profile

uuid00022d2

Namestring
Novaliq
Legal namestring
Novaliq GmbH
Websiteurl
novaliq.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Novaliq GmbH is a Heidelberg, Germany-based biopharmaceutical company founded in 2007 that develops and commercializes ocular therapeutics built on its proprietary EyeSol® water-free drug-delivery platform. EyeSol® uses semifluorinated alkanes — primarily perfluorohexyloctane — as the carrier medium instead of water, enabling preservative-free, micro-dosed topical ophthalmic formulations with enhanced corneal penetration, longer ocular surface residence time, and no vision blurring. The company's portfolio includes two FDA-approved prescription products launched in 2023 — CyclASol® (cyclosporine 0.1%, marketed as VEVYE™ in USA/Canada and Vevizye® in Europe) and NOV03 (perfluorohexyloctane, marketed as MIEBO™ in USA/Canada and Heng Qin® in China) — both for dry eye disease, plus the over-the-counter NovaTears® / NovaTears®+Omega-3 line commercialized since 2013.

The company operates an asset-light, licensing-driven business model: prescription products are developed in-house through Phase 3 and then out-licensed by geography to established ophthalmic commercial partners — Bausch + Lomb and Harrow in USA/Canada, Laboratoires Théa in Europe/MENA, Senju in Japan, and Jiangsu Hengrui in China — generating upfront payments, development and regulatory milestones, and tiered royalties on net sales. OTC products are distributed through Ursapharm in Europe (under the EvoTears® brand across 17 countries) and AFT Pharmaceuticals in Australia/New Zealand (PBS-listed since 2018). Novaliq also pursues adjacent ophthalmic indications through a glaucoma joint venture (Betaliq Inc., with BLP Management Group), a diabetic retinopathy R&D program, and a dermatology spin-off (Dermaliq Therapeutics), with FDA IND clearance in January 2026 to advance NOV05 into Phase II for non-infectious anterior uveitis.

Novaliq is privately held, with dievini Hopp BioTech Holding as long-term anchor shareholder (lead investor across multiple financing rounds totaling approximately $115 million since inception, including a $53 million round in October 2018 and a $15 million round in April 2022). The company maintains a U.S. subsidiary (Novaliq Inc., Cambridge, MA, established January 2018) and a lean headcount of 51–100 employees, with clinical execution supported by leading ophthalmic CRO Ora, Inc. and academic collaborations with the University of Cologne, Queen's University Belfast, and University of Auckland. Customer reach is global, spanning North America, Europe, MENA, China, Japan, Australia, and New Zealand.

Short descriptiontext

Novaliq is a private German biopharmaceutical company developing preservative-free ophthalmic therapeutics based on its proprietary EyeSol® water-free drug-delivery platform, commercializing FDA-approved dry eye treatments (VEVYE and MIEBO) via global licensing partnerships with major eyecare companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHeidelberg, Germany
HQ citystring
Heidelberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, dry eye therapeutics, water-free drug delivery, ocular therapeutics, prescription eye drops
Industry2 codes
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Novaliq generates revenue through licensing agreements with pharmaceutical partners for development and commercialization rights. Partners pay upfront payments, development/regulatory milestones, and ongoing royalties on net sales.

novaliq.com
2Direct Product Revenue (Europe/Australasia)
TypeHardware Sales
Description

NovaTears and NovaTears+Omega-3 are commercialized through distribution partners (Ursapharm in Europe, AFT Pharmaceuticals in Australia/New Zealand) generating product revenue streams.

novaliq.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1NovaTears
Description

First water-free eye drop based on EyeSol for treatment of dry eye disease. CE certified since 2013, commercialized in Europe (as EvoTears) and Australia/New Zealand

novaliq.com
+7 more records
Core offering1 text field

Novaliq develops and commercializes first- and best-in-class ocular therapeutics based on its proprietary EyeSol® water-free technology platform. The company manufactures prescription pharmaceuticals (CyclASol/VEVYE/Vevizye and NOV03/MIEBO) and over-the-counter eye drops (NovaTears, NovaTears+Omega-3) for the treatment of dry eye disease and meibomian gland dysfunction, licensing global commercialization rights to major pharmaceutical partners while generating revenue through upfront payments, milestones, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • NOV03 showed statistically significant improvement in total corneal fluorescein staining at Day 15 (p=0.001) and Day 57 (p<0.001) compared to control in Phase 3 GOBI trial.
+4 more records
Product overview1 text field

Novaliq is a biopharmaceutical company focused on ophthalmology, offering a portfolio of prescription and over-the-counter eye disease treatments. The product portfolio centers on two proprietary technology platforms: EyeSol® water-free technology (used by CyclASol®/VEVYE™/Vevizye®) and perfluorohexyloctane-based formulations (used by NOV03/MIEBO™/Heng Qin® and NovaTears®). CyclASol® and NOV03 represent the company's flagship prescription pharmaceuticals approved for dry eye disease treatment, while NovaTears® and NovaTears®+Omega-3 serve the OTC market. The company also maintains a pipeline including BTQ 1901 and BTQ 1902 for glaucoma through its Betaliq subsidiary.

Product and service7 records
1CyclASol® (VEVYE™ in US/Canada, Vevizye® in Europe)
CategoryPrescription Pharmaceutical
Description

Cyclosporine ophthalmic solution 0.1% based on EyeSol® water-free technology, an anti-inflammatory treatment for dry eye disease indicated for both signs and symptoms. FDA approved May 30, 2023 and EC approved October 2024.

2NOV03 (MIEBO™ in US/Canada, Heng Qin® in China)
CategoryPrescription Pharmaceutical
Description

Perfluorohexyloctane ophthalmic solution based on EyeSol® technology, the first FDA-approved treatment that directly targets tear evaporation for dry eye disease associated with meibomian gland dysfunction.

3NovaTears®
CategoryOver-the-Counter Pharmaceutical
Description

Perfluorohexyloctane-based water-free eye drop for treatment of dry eye disease. CE certified since 2013, commercialized in Europe (as EvoTears) and Australia/New Zealand (PBS listed).

4NovaTears®+Omega-3
CategoryOver-the-Counter Pharmaceutical
Description

Eye drop formulation containing high dose of algae-derived omega-3 fatty acids (0.2%) combined with water-free EyeSol® technology platform for enhanced dry eye treatment.

5EvoTears®
CategoryOver-the-Counter Pharmaceutical
Description

European brand name for NovaTears® (perfluorohexyloctane) based on water-free EyeSol® technology for dry eye treatment, distributed in 17 European countries including Germany, France, UK, Spain, Italy, Benelux, Poland, and Switzerland.

6BTQ 1902
CategoryPipeline Candidate
Description

Glaucoma treatment candidate (timolol in EyeSol) being developed by Betaliq Inc., a Novaliq joint venture with BLP Management Group, focused on ophthalmic beta-blockers using EyeSol water-free technology.

7BTQ 1901
CategoryPipeline Candidate
Description

Novel ophthalmic beta-blocker candidate in the Novaliq/Betaliq pipeline for glaucoma treatment using EyeSol technology.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-10-02
Description

European Commission approved Vevizye (ciclosporin 0.1% eye drops solution) and partnership with Théa for commercialization in Europe and selected MENA countries. Théa is the leading independent eye care group in Europe.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-07-18
Description

Harrow acquired U.S. and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1% from Novaliq. VEVYE is the first and only cyclosporine-based product indicated for treatment of both signs and symptoms of dry eye disease. FDA approved May 30, 2023.

3Senju Pharmaceutical Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-06-13
Description

License agreement for NOV03 (perfluorohexyloctane ophthalmic solution) development, manufacturing, and commercialization in Japan. Senju is a research-based Japanese pharmaceutical company focusing on ophthalmology.

novaliq.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-12-20
Description

Exclusive license agreement for NOV03 (perfluorohexyloctane) development and commercialization in USA and Canada. Bausch + Lomb acquired rights in December 2019. MIEBO received FDA approval in May 2023 for treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction. It is the first and only FDA-approved treatment that directly targets tear evaporation.

5Jiangsu Hengrui Pharmaceuticals
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-11-08
Description

Strategic collaboration for NOV03 and CyclASol in China (mainland, Hong Kong, Macau, Taiwan). Hengrui received exclusive rights to develop, manufacture, and commercialize both drugs. Novaliq eligible for upfront payment of up to $9 million, milestone payments up to $156 million, plus tiered royalties. Hengrui is a leading biopharma in China with $2.5 billion annual net sales in 2018.

novaliq.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-04-25
Description

Joint venture with BLP Management Group in Tampa, Florida to develop ophthalmic beta-blockers using EyeSol technology. Betaliq developing BTQ 1901 (novel beta-blocker) and BTQ 1902 (timolol in EyeSol) for glaucoma treatment. Series A financing completed. Phase 2 clinical trial initiated April 2021.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-12-24
Description

Research collaboration for development of novel topical ophthalmic formulations of Nicox's NO-donating PDE5 inhibitors based on EyeSol technology for lowering intraocular pressure (IOP) in glaucoma treatment.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Commercialization partner for EvoTears (perfluorohexyloctane) in Europe. EvoTears launched in 17 European countries including Germany, France, UK, Spain, Italy, Benelux, Poland, and Switzerland. Also distributed as HYLO LIPID in France and Hycosan Shield in UK.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for NovaTears and NovaTears+Omega-3 in Australia and New Zealand. Products are PBS listed in Australia since September 2018. AFT is an ASX/NZX listed company and leader in lubricating eyecare category in Australia.

10Prof. Dr. med. Claus Cursiefen
Strategic tierMinorTypeOthers
Description

Academic partner at University of Cologne for ophthalmic drug delivery research for anterior segment of eye with special focus on dry eye disease.

novaliq.com
11Prof. Heping Xu
Strategic tierMinorTypeOthers
Description

Academic partner at Queen's University for retina diseases research.

novaliq.com
12Dr. Ilva Rupenthal
Strategic tierMinorTypeOthers
Description

Academic partner at University of Auckland for drug delivery technologies and ocular therapeutics research.

novaliq.com
Strategic tierCoreTypeOthers
Description

World's leading full-service ophthalmic CRO conducting clinical trials for CyclASol ESSENCE-2 trial in approximately 25 U.S. clinical centers with approximately 834 subjects.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global ophthalmology major that licenses NOV03/MIEBO from Novaliq for US/Canada. Compares as a peer because it operates in the same Rx ophthalmology commercial channel and competes for physician share-of-voice in dry eye with Novaliq's other drug VEVYE.

TypeDirect peer
Description

US-focused ophthalmic pharmaceutical company that licenses and commercializes VEVYE in US/Canada. Highly comparable as a recent-stage commercializer of branded ophthalmology specialty products with similar GTM to eye-care practitioners.

TypeDirect peer
Description

Leading independent European eye-care group that licenses Vevizye from Novaliq for EU/MENA. Direct peer via the partnership, and comparable as a specialty ophthalmology company operating with independent commercial reach across European eyecare channels.

4Senju Pharmaceutical
TypeRegional player
Description

Japanese research-based ophthalmology company licensing NOV03 for the Japan market. Comparable as a regionally-dominant ophthalmic pharma partner but operates primarily in Asia rather than directly competing with Novaliq elsewhere.

TypeEmerging player
Description

US clinical-stage biotech developing novel reproxalap for dry eye disease. Comparable as an emerging ophthalmology specialty challenger pursuing novel mechanisms against the same DED market Novaliq targets with MIEBO/VEVYE.

TypeBroad incumbent
Description

Pre-acquisition Aerie was a specialty ophthalmology player focused on glaucoma; acquired by Alcon in 2022. Comparable as a specialty ophthalmic pharma company with branded Rx products targeting the same physician call-point Novaliq pursues.

TypeEmerging player
Description

US specialty ophthalmic company that developed Tyrvaya for dry eye disease before being acquired. Comparable as a recent-stage innovator with a single specialty ophthalmology product reaching commercialization.

TypeEmerging player
Description

European ophthalmic R&D company developing NO-donating therapeutics including via collaboration with Novaliq's EyeSol. Comparable as a clinical/specialty ophthalmology company and an actual development partner with overlapping technology interests in glaucoma.

TypeEmerging player
Description

Specialty ophthalmic company that developed Eysuvis for dry eye disease flares. Comparable as a single-asset-focused DED challenger that targeted the same underserved prescriber channel.

TypeBroad incumbent
Description

Maker of Restasis, the legacy cyclosporine dry-eye therapy that VEVYE now competes against directly. Broad incumbent in ophthalmology Rx, providing the entrenched benchmark Novaliq is displacing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novaliq

Ophthalmic Pharmaceuticalsnovaliq.com

Novaliq is a private German biopharmaceutical company developing preservative-free ophthalmic therapeutics based on its proprietary EyeSol® water-free drug-delivery platform, commercializing FDA-approved dry eye treatments (VEVYE and MIEBO) via global licensing partnerships with major eyecare companies.

What Novaliq does

Novaliq GmbH is a Heidelberg, Germany-based biopharmaceutical company founded in 2007 that develops and commercializes ocular therapeutics built on its proprietary EyeSol® water-free drug-delivery platform. EyeSol® uses semifluorinated alkanes — primarily perfluorohexyloctane — as the carrier medium instead of water, enabling preservative-free, micro-dosed topical ophthalmic formulations with enhanced corneal penetration, longer ocular surface residence time, and no vision blurring. The company's portfolio includes two FDA-approved prescription products launched in 2023 — CyclASol® (cyclosporine 0.1%, marketed as VEVYE™ in USA/Canada and Vevizye® in Europe) and NOV03 (perfluorohexyloctane, marketed as MIEBO™ in USA/Canada and Heng Qin® in China) — both for dry eye disease, plus the over-the-counter NovaTears® / NovaTears®+Omega-3 line commercialized since 2013.

The company operates an asset-light, licensing-driven business model: prescription products are developed in-house through Phase 3 and then out-licensed by geography to established ophthalmic commercial partners — Bausch + Lomb and Harrow in USA/Canada, Laboratoires Théa in Europe/MENA, Senju in Japan, and Jiangsu Hengrui in China — generating upfront payments, development and regulatory milestones, and tiered royalties on net sales. OTC products are distributed through Ursapharm in Europe (under the EvoTears® brand across 17 countries) and AFT Pharmaceuticals in Australia/New Zealand (PBS-listed since 2018). Novaliq also pursues adjacent ophthalmic indications through a glaucoma joint venture (Betaliq Inc., with BLP Management Group), a diabetic retinopathy R&D program, and a dermatology spin-off (Dermaliq Therapeutics), with FDA IND clearance in January 2026 to advance NOV05 into Phase II for non-infectious anterior uveitis.

Novaliq is privately held, with dievini Hopp BioTech Holding as long-term anchor shareholder (lead investor across multiple financing rounds totaling approximately $115 million since inception, including a $53 million round in October 2018 and a $15 million round in April 2022). The company maintains a U.S. subsidiary (Novaliq Inc., Cambridge, MA, established January 2018) and a lean headcount of 51–100 employees, with clinical execution supported by leading ophthalmic CRO Ora, Inc. and academic collaborations with the University of Cologne, Queen's University Belfast, and University of Auckland. Customer reach is global, spanning North America, Europe, MENA, China, Japan, Australia, and New Zealand.

Novaliq firmographics

Firmographics
Name
Novaliq
Legal name
Novaliq GmbH
Website
https://novaliq.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Novaliq is a private German biopharmaceutical company developing preservative-free ophthalmic therapeutics based on its proprietary EyeSol® water-free drug-delivery platform, commercializing FDA-approved dry eye treatments (VEVYE and MIEBO) via global licensing partnerships with major eyecare companies.
Ownership category
akta.pro rank

Novaliq industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic pharmaceuticals
  • Dry eye therapeutics
  • Water-free drug delivery
  • Ocular therapeutics
  • Prescription eye drops

Where Novaliq is headquartered

Location

Headquarters

HQ city
Heidelberg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Novaliq business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and Royalty Revenue: Novaliq generates revenue through licensing agreements with pharmaceutical partners for development and commercialization rights. Partners pay upfront payments, development/regulatory milestones, and ongoing royalties on net sales.
  2. Direct Product Revenue (Europe/Australasia): NovaTears and NovaTears+Omega-3 are commercialized through distribution partners (Ursapharm in Europe, AFT Pharmaceuticals in Australia/New Zealand) generating product revenue streams.

Go-to-market motion2 records

Distribution channels7 records

Marketing channels5 records

Novaliq product offering

Product offering

Core offering

Novaliq develops and commercializes first- and best-in-class ocular therapeutics based on its proprietary EyeSol® water-free technology platform. The company manufactures prescription pharmaceuticals (CyclASol/VEVYE/Vevizye and NOV03/MIEBO) and over-the-counter eye drops (NovaTears, NovaTears+Omega-3) for the treatment of dry eye disease and meibomian gland dysfunction, licensing global commercialization rights to major pharmaceutical partners while generating revenue through upfront payments, milestones, and royalties.

Product overview

Novaliq is a biopharmaceutical company focused on ophthalmology, offering a portfolio of prescription and over-the-counter eye disease treatments. The product portfolio centers on two proprietary technology platforms: EyeSol® water-free technology (used by CyclASol®/VEVYE™/Vevizye®) and perfluorohexyloctane-based formulations (used by NOV03/MIEBO™/Heng Qin® and NovaTears®). CyclASol® and NOV03 represent the company's flagship prescription pharmaceuticals approved for dry eye disease treatment, while NovaTears® and NovaTears®+Omega-3 serve the OTC market. The company also maintains a pipeline including BTQ 1901 and BTQ 1902 for glaucoma through its Betaliq subsidiary.

Differentiator

Problem solved

Functional benefit

Brands

  • NovaTears: First water-free eye drop based on EyeSol for treatment of dry eye disease. CE certified since 2013, commercialized in Europe (as EvoTears) and Australia/New Zealand
  • NovaTears+Omega-3
  • CyclASol
  • NOV03
  • VEVYE
  • MIEBO
  • EvoTears
  • EyeSol

Products and services

  • CyclASol® (VEVYE™ in US/Canada, Vevizye® in Europe) Cyclosporine ophthalmic solution 0.1% based on EyeSol® water-free technology, an anti-inflammatory treatment for dry eye disease indicated for both signs and symptoms. FDA approved May 30, 2023 and EC approved October 2024.
  • NOV03 (MIEBO™ in US/Canada, Heng Qin® in China) Perfluorohexyloctane ophthalmic solution based on EyeSol® technology, the first FDA-approved treatment that directly targets tear evaporation for dry eye disease associated with meibomian gland dysfunction.
  • NovaTears® Perfluorohexyloctane-based water-free eye drop for treatment of dry eye disease. CE certified since 2013, commercialized in Europe (as EvoTears) and Australia/New Zealand (PBS listed).
  • NovaTears®+Omega-3 Eye drop formulation containing high dose of algae-derived omega-3 fatty acids (0.2%) combined with water-free EyeSol® technology platform for enhanced dry eye treatment.
  • EvoTears® European brand name for NovaTears® (perfluorohexyloctane) based on water-free EyeSol® technology for dry eye treatment, distributed in 17 European countries including Germany, France, UK, Spain, Italy, Benelux, Poland, and Switzerland.
  • BTQ 1902 Glaucoma treatment candidate (timolol in EyeSol) being developed by Betaliq Inc., a Novaliq joint venture with BLP Management Group, focused on ophthalmic beta-blockers using EyeSol water-free technology.
  • BTQ 1901 Novel ophthalmic beta-blocker candidate in the Novaliq/Betaliq pipeline for glaucoma treatment using EyeSol technology.

Quantifiable outcome

  • NOV03 showed statistically significant improvement in total corneal fluorescein staining at Day 15 (p=0.001) and Day 57 (p<0.001) compared to control in Phase 3 GOBI trial.
  • +4 more outcomes

Companies that use Novaliq

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Novaliq technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Novaliq partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Laboratoires ThéacoreChannel Partner/ Reseller/ Distributor · 2 October 2024European Commission approved Vevizye (ciclosporin 0.1% eye drops solution) and partnership with Théa for commercialization in Europe and selected MENA countries. Théa is the leading independent eye care group in Europe.
  • HarrowcoreChannel Partner/ Reseller/ Distributor · 18 July 2023Harrow acquired U.S. and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1% from Novaliq. VEVYE is the first and only cyclosporine-based product indicated for treatment of both signs and symptoms of dry eye disease. FDA approved May 30, 2023.
  • Senju Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 13 June 2023License agreement for NOV03 (perfluorohexyloctane ophthalmic solution) development, manufacturing, and commercialization in Japan. Senju is a research-based Japanese pharmaceutical company focusing on ophthalmology.
  • Bausch + LombcoreChannel Partner/ Reseller/ Distributor · 20 December 2019Exclusive license agreement for NOV03 (perfluorohexyloctane) development and commercialization in USA and Canada. Bausch + Lomb acquired rights in December 2019. MIEBO received FDA approval in May 2023 for treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction. It is the first and only FDA-approved treatment that directly targets tear evaporation.
  • Jiangsu Hengrui PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 8 November 2019Strategic collaboration for NOV03 and CyclASol in China (mainland, Hong Kong, Macau, Taiwan). Hengrui received exclusive rights to develop, manufacture, and commercialize both drugs. Novaliq eligible for upfront payment of up to $9 million, milestone payments up to $156 million, plus tiered royalties. Hengrui is a leading biopharma in China with $2.5 billion annual net sales in 2018.
  • Betaliq Inc.coreStrategic or Co-development Partner · 25 April 2019Joint venture with BLP Management Group in Tampa, Florida to develop ophthalmic beta-blockers using EyeSol technology. Betaliq developing BTQ 1901 (novel beta-blocker) and BTQ 1902 (timolol in EyeSol) for glaucoma treatment. Series A financing completed. Phase 2 clinical trial initiated April 2021.
  • NicoxminorStrategic or Co-development Partner · 24 December 2018Research collaboration for development of novel topical ophthalmic formulations of Nicox's NO-donating PDE5 inhibitors based on EyeSol technology for lowering intraocular pressure (IOP) in glaucoma treatment.
  • UrsapharmcoreChannel Partner/ Reseller/ DistributorCommercialization partner for EvoTears (perfluorohexyloctane) in Europe. EvoTears launched in 17 European countries including Germany, France, UK, Spain, Italy, Benelux, Poland, and Switzerland. Also distributed as HYLO LIPID in France and Hycosan Shield in UK.
  • AFT PharmaceuticalscoreChannel Partner/ Reseller/ DistributorDistribution partner for NovaTears and NovaTears+Omega-3 in Australia and New Zealand. Products are PBS listed in Australia since September 2018. AFT is an ASX/NZX listed company and leader in lubricating eyecare category in Australia.
  • Prof. Dr. med. Claus CursiefenminorOthersAcademic partner at University of Cologne for ophthalmic drug delivery research for anterior segment of eye with special focus on dry eye disease.
  • Prof. Heping XuminorOthersAcademic partner at Queen's University for retina diseases research.
  • Dr. Ilva RupenthalminorOthersAcademic partner at University of Auckland for drug delivery technologies and ocular therapeutics research.
  • Ora, Inc.coreOthersWorld's leading full-service ophthalmic CRO conducting clinical trials for CyclASol ESSENCE-2 trial in approximately 25 U.S. clinical centers with approximately 834 subjects.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Novaliq competitors and assessment

Company assessment

Direct peers

  • Bausch + Lomb (Bausch Health): Global ophthalmology major that licenses NOV03/MIEBO from Novaliq for US/Canada. Compares as a peer because it operates in the same Rx ophthalmology commercial channel and competes for physician share-of-voice in dry eye with Novaliq's other drug VEVYE.
  • Harrow Health: US-focused ophthalmic pharmaceutical company that licenses and commercializes VEVYE in US/Canada. Highly comparable as a recent-stage commercializer of branded ophthalmology specialty products with similar GTM to eye-care practitioners.
  • Laboratoires Théa: Leading independent European eye-care group that licenses Vevizye from Novaliq for EU/MENA. Direct peer via the partnership, and comparable as a specialty ophthalmology company operating with independent commercial reach across European eyecare channels.

Regional players

  • Senju Pharmaceutical: Japanese research-based ophthalmology company licensing NOV03 for the Japan market. Comparable as a regionally-dominant ophthalmic pharma partner but operates primarily in Asia rather than directly competing with Novaliq elsewhere.

Emerging players

  • Aldeyra Therapeutics: US clinical-stage biotech developing novel reproxalap for dry eye disease. Comparable as an emerging ophthalmology specialty challenger pursuing novel mechanisms against the same DED market Novaliq targets with MIEBO/VEVYE.
  • Oyster Point Pharma: US specialty ophthalmic company that developed Tyrvaya for dry eye disease before being acquired. Comparable as a recent-stage innovator with a single specialty ophthalmology product reaching commercialization.
  • Nicox: European ophthalmic R&D company developing NO-donating therapeutics including via collaboration with Novaliq's EyeSol. Comparable as a clinical/specialty ophthalmology company and an actual development partner with overlapping technology interests in glaucoma.
  • Kala Pharmaceuticals: Specialty ophthalmic company that developed Eysuvis for dry eye disease flares. Comparable as a single-asset-focused DED challenger that targeted the same underserved prescriber channel.

Broad incumbents

  • Aerie Pharmaceuticals (Alcon): Pre-acquisition Aerie was a specialty ophthalmology player focused on glaucoma; acquired by Alcon in 2022. Comparable as a specialty ophthalmic pharma company with branded Rx products targeting the same physician call-point Novaliq pursues.
  • Allergan / AbbVie: Maker of Restasis, the legacy cyclosporine dry-eye therapy that VEVYE now competes against directly. Broad incumbent in ophthalmology Rx, providing the entrenched benchmark Novaliq is displacing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Novaliq social profiles

Digital presence

Novaliq financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novaliq leadership team

Management profile

Number of profiles

Profiles8 records

Novaliq subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Novaliq funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novaliq M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novaliq

What does Novaliq do?

Novaliq develops and commercializes first- and best-in-class ocular therapeutics based on its proprietary EyeSol® water-free technology platform. The company manufactures prescription pharmaceuticals (CyclASol/VEVYE/Vevizye and NOV03/MIEBO) and over-the-counter eye drops (NovaTears, NovaTears+Omega-3) for the treatment of dry eye disease and meibomian gland dysfunction, licensing global commercialization rights to major pharmaceutical partners while generating revenue through upfront payments, milestones, and royalties.

Is Novaliq a public or private company?

Novaliq is a private company. It is classified as venture growth investor backed and is currently operating.

When was Novaliq founded?

Novaliq was founded in 2007. It employs 11 to 50 people.

Where is Novaliq based?

Novaliq is headquartered in Heidelberg, Germany, in the Europe region.

How does Novaliq make money?

Two revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are direct Product Revenue (Europe/Australasia).

Who are Novaliq's main competitors?

Direct peers on record are Bausch + Lomb (Bausch Health), Harrow Health and Laboratoires Théa. Senju Pharmaceutical is listed as a regional player. Emerging players are Aldeyra Therapeutics, Oyster Point Pharma, Nicox and Kala Pharmaceuticals. Broad incumbents are Aerie Pharmaceuticals (Alcon) and Allergan / AbbVie.

Does Novaliq have an API?

No public API is recorded for Novaliq.

What industry is Novaliq in?

Novaliq's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAutoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsightThe autoimmune uveitis market is projected to grow at a 7% CAGR from 2026 to 2036, with the 7MM market valued at USD 1.2 billion in 2025. Growth is driven by rising prevalence, demand for steroid-sparing therapies, and novel treatments like Brepocitinib and TRS01. Emerging therapies are expected to reshape the market landscape.Business Wire BlogHengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye DiseaseOn June 23, 2026, the China National Medical Products Administration (NMPA) approved Hengrui Pharma's Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of dry eye disease in China, making it the first and only water-free cyclosporine ophthalmic solution and the second dry eye disease drug based on the EyeSol® platform technology approved in China. The approval was based on a Phase III clinical trial (SHR8028-301) that demonstrated significant improvement in corneal fluorescein staining scores as early as Day 15 compared to vehicle control. Hengrui Pharma and Novaliq GmbH, which entered a strategic collaboration in 2019 granting Hengrui exclusive rights to develop, manufacture, and commercialize the product in China, are jointly announcing this approval.FinancialContent Business PageHengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye DiseaseOn June 23, 2026, China's National Medical Products Administration (NMPA) approved Hengrui Pharma's Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of dry eye disease, following a strategic collaboration with Novaliq GmbH. Heng Yi® is the first and only water-free cyclosporine ophthalmic solution and the second dry eye drug based on Novaliq's EyeSol® platform technology approved in China. The Phase III clinical trial demonstrated significant efficacy with treatment group tCFS score improvements of -4.0 at Day 15 and -4.8 at Day 29 compared to vehicle control.EyeWorldEyeWorld, January 30, 2026Orasis Pharmaceuticals announced research findings that its low-dose pilocarpine formulation, Qlosi, reduces pupil diameter without significant ciliary muscle response, balancing efficacy and safety compared to higher doses. Additionally, the FDA approved an IND for Novaliq's steroid-free anti-inflammatory treatment NOV05, enabling Phase 2 trials for anterior uveitis. Orasis also highlighted a favorable safety profile with no serious adverse events reported during real-world use.Business Wire BlogNovaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)Novaliq and Laboratoires Théa announced European Commission approval of Vevizye (ciclosporin 0.1% eye drops) and Théa's acquisition of commercialization rights in Europe and selected MENA countries. The product is the only water-free ciclosporin eye drops approved in the EU for moderate to severe dry eye disease. Additional regulatory applications are under review in China, Australia, and New Zealand.Endpoints NewsBausch + Lomb and No­valiq win ap­proval for dry eye dis­ease treat­mentBausch + Lomb and Novaliq secured approval for their dry eye disease drop, to be marketed as Miebo. The drug, also known as ...Business Wire BlogBausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye DiseaseBausch + Lomb and Novaliq announced FDA approval of MIEBO, a prescription eye drop for dry eye disease, the first and only treatment targeting tear evaporation. The approval was based on two phase 3 trials with over 1,200 patients, and commercial availability is expected in the second half of this year.BioSpaceBausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of OphthalmologyBausch + Lomb and Novaliq published second pivotal Phase 3 data for NOV03 in the American Journal of Ophthalmology, showing it met primary endpoints for dry eye disease associated with meibomian gland dysfunction. The FDA assigned a PDUFA action date of June 28, 2023, and the company expects new topline data later this year.PR NewswireDry Eye Products Global Market Report 2022: Sector to Reach $9.68 Billion by 2028 at a 5.1% CAGRResearchAndMarkets.com published a market report projecting the global dry eye products market to grow from $6.84 billion in 2021 to $9.68 billion by 2028, representing a compound annual growth rate of 5.1%. The report identifies rising dry eye incidences and an expanding geriatric population as primary growth drivers, while side effects from eye drops are cited as a potential market impediment. Companies such as Aldeyra Therapeutics and Novaliq are highlighted for their active clinical pipeline development in the sector.BioSpaceBausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in OphthalmologyBausch + Lomb and Novaliq announced publication of Phase 3 trial GOBI data for NOV03 in Ophthalmology, showing significant improvements in dry eye symptoms. The FDA assigned a PDUFA action date of June 28, 2023, and the trial met both co-primary endpoints.